Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)
NCT00089960 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 138
Last updated 2013-04-29
Summary
This study will determine the safety and effectiveness of AMG 706 in patients with advanced GIST.
Conditions
Interventions
- DRUG
-
AMG 706
AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-10-31
- Primary Completion
- 2006-06-30
- Completion
- 2008-06-30
More Related Trials
-
Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index
NCT02576080 ·Status: UNKNOWN ·Phase: PHASE3
-
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
NCT00171977 ·Status: COMPLETED ·Phase: PHASE4
-
Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)
NCT01483014 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
NCT00940563 ·Status: COMPLETED ·Phase: PHASE2
-
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
NCT00867113 ·Status: COMPLETED ·Phase: PHASE2
-
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
NCT00500188 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
NCT00028002 ·Status: COMPLETED ·Phase: PHASE2
-
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
NCT00041197 ·Status: COMPLETED ·Phase: PHASE3
-
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg
NCT00751036 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT06655246 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
NCT00237185 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
NCT00009906 ·Status: TERMINATED ·Phase: PHASE3
-
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
NCT01089595 ·Status: TERMINATED ·Phase: PHASE2
-
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
NCT00112632 ·Status: COMPLETED ·Phase: PHASE2
-
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
NCT00025246 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Surival of GIST Patients ≥ 10 Years on Imatinib
NCT04097093 ·Status: WITHDRAWN
-
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
NCT05009927 ·Status: RECRUITING ·Phase: PHASE2
-
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
NCT02257541 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
NCT01267695 ·Status: COMPLETED ·Phase: PHASE2
-
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
NCT00764595 ·Status: COMPLETED ·Phase: PHASE2
-
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
NCT00103168 ·Status: COMPLETED ·Phase: PHASE3
-
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
NCT02260505 ·Status: COMPLETED ·Phase: PHASE3
-
A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.
NCT01227746 ·Status: UNKNOWN
-
Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer
NCT00041340 ·Status: COMPLETED ·Phase: PHASE2
-
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
NCT00441155 ·Status: COMPLETED ·Phase: PHASE1